Evidence map›Paper›PMID 34897925›Full record

ArticleHIV medicine2022

The incidence of and risk factors for hospitalized acute kidney injury among people living with HIV on antiretroviral treatment.

Anthony N Muiru, Erin Madden, Ani Chilingirian, Anna D Rubinsky, Rebecca Scherzer, Richard Moore, Celia P Corona Villalobos, Jose Manuel Monroy Trujillo, Chirag R Parikh, Chi-Yuan Hsu and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HIV medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Anthony N MuiruKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, CA, USA.ORCID 0000-0003-2622-9658
Erin MaddenKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, CA, USA.
Ani ChilingirianKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, CA, USA.
Anna D RubinskyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.
Rebecca ScherzerKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, CA, USA.
Richard MooreDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Celia P Corona VillalobosDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jose Manuel Monroy TrujilloDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Chirag R ParikhDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Chi-Yuan HsuDivision of Nephrology, Department of Medicine, University of California, San Francisco, CA, USA.
Michael G ShlipakKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, CA, USA.
Michelle M EstrellaKidney Health Research Collaborative, Department of Medicine, University of California, San Francisco, CA, USA.
University of California, San Francisco · USJohns Hopkins University · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
Renal Physiology and Phenotyping CoreP30DK079310 · NIDDK · YALE UNIVERSITY · PI SOMLO, STEFAN · 2008 to 2022
$16.8M
Johns Hopkins HIV Clinical CohortU01DA036935 · NIDA · JOHNS HOPKINS UNIVERSITY · PI MOORE, RICHARD DOUGLAS · 2014 to 2024
$14.9M
Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3M
Biomarkers of Kidney Injury to Predict AKI Onset and Progression in HIV InfectionR01DK103574 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ESTRELLA, MICHELLE M · 2015 to 2020
$3.4M
Acute kidney injury among patients with chronic kidney diseaseR01DK114014 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2018 to 2021
$3.0M
Patient Oriented Research in Kidney DiseaseK24DK092291 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 2011 to 2020
$1.2M
SEARCH-CKD: The nature of chronic kidney disease and elevated blood pressure in sub-Saharan Africa.K23DK119562 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MUIRU, ANTHONY N · 2021 to 2025
$1.0M
NHLBI NIH HHS R01 HL085757NIAID NIH HHS P30 AI094189NIDA NIH HHS U01 DA036935NIDDK NIH HHS K23 DK119562NIDDK NIH HHS K24 DK092291NIDDK NIH HHS P30 DK079310NIDDK NIH HHS R01 DK103574NIDDK NIH HHS R01 DK114014
6 · The paper itself

Abstract

objectivesThe epidemiology of hospitalized acute kidney injury (AKI) among people living with HIV (PLWH) in the era of modern antiretroviral therapy (ART) for all PLWH is not well characterized. We evaluated the incidence of and risk factors for hospitalized AKI from 2005 to 2015 among PLWH on ART.

methodsWe conducted a retrospective analysis of PLWH from the Johns Hopkins HIV Clinical Cohort. We defined hospitalized AKI as a rise of ≥ 0.3 mg/dL in serum creatinine (SCr) within any 48-h period or a 50% increase in SCr from baseline and assessed associations of risk factors with incident AKI using multivariate Cox regression models.

resultsMost participants (75%) were black, 34% were female, and the mean age was 43 years. The incidence of AKI fluctuated annually, peaking at 40 per 1000 person-years (PY) [95% confidence interval (CI) 22-69 per 1000 PY] in 2007, and reached a nadir of 20 per 1000 PY (95% CI 11-34 per 1000 PY) in 2010. There was no significant temporal trend (-3.3% change per year; 95% CI -8.6 to 2.3%; P = 0.24). After multivariable adjustment, characteristics independently associated with AKI included black race [hazard ratio (HR) 2.44; 95% CI 1.42-4.20], hypertension (HR 1.62; 95% CI 1.09-2.38), dipstick proteinuria > 1 (HR 1.86; 95% CI 1.07-3.23), a history of AIDS (HR 1.82; 95% CI 1.29-2.56), CD4 count < 200 cells/µL (HR 1.46; 95% CI 1.02-2.07), and lower serum albumin (HR 1.73 per 1 g/dL decrease; 95% CI 1.02-2.07).

conclusionsIn this contemporary cohort of PLWH, the annual incidence of first AKI fluctuated during the study period. Attention to modifiable AKI risk factors and social determinants of health may further reduce AKI incidence among PLWH.

Indexed as

Acute Kidney InjuryHIV InfectionsAdultAnti-Retroviral AgentsFemaleHumansIncidenceMaleRetrospective StudiesRisk FactorsAnti-Retroviral Agentsacute kidney injuryantiretroviral therapychronic kidney diseaseHIVproteinuria

Identifiers

PMID34897925
PMCPMC9177550
OpenAlexW4200104326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.